Previous studies demonstrate that loss of Nur77 expression is a key pathological factor in the development of AML, and pharmacological target of Nur77 provides a novel approach for the therapeutic intervention in AML (Mullican et al., 2007; Boudreaux et al., 2019). Here, NR4A1 is linked to acute myeloid leukemia.